129 related articles for article (PubMed ID: 25770767)
1. Deferred systemic therapy in patients with metastatic renal cell carcinoma.
Mitchell AP; Hirsch BR; Harrison MR; Abernethy AP; George DJ
Clin Genitourin Cancer; 2015 Jun; 13(3):e159-66. PubMed ID: 25770767
[TBL] [Abstract][Full Text] [Related]
2. Patterns of care for metastatic renal cell carcinoma in Australia.
Day D; Kanjanapan Y; Kwan E; Yip D; Lawrentschuk N; Andrews M; Davis ID; Azad AA; Rosenthal M; Wong S; Johnstone A; Gibbs P; Tran B
BJU Int; 2015 Oct; 116 Suppl 3():36-41. PubMed ID: 26204961
[TBL] [Abstract][Full Text] [Related]
3. [The significance of metastasectomy in patients with metastatic renal cell carcinoma].
Miyata H; Shinohara N; Murahashi N; Tsuchiya K; Miyajima N; Maruyama S; Abe T; Kaga K; Hirano S; Nonomura K
Hinyokika Kiyo; 2015 Feb; 61(2):49-54. PubMed ID: 25812593
[TBL] [Abstract][Full Text] [Related]
4. Five-year Survival of Patients With Metastatic Renal Cell Carcinoma in the Russian Federation: Results From the RENSUR5 Registry.
Tsimafeyeu I; Zolotareva T; Varlamov S; Zukov R; Petkau V; Mazhbich M; Statsenko G; Safina S; Zaitsev I; Sakaeva D; Popov A; Borisov P; Vladimirova L
Clin Genitourin Cancer; 2017 Dec; 15(6):e1069-e1072. PubMed ID: 28882737
[TBL] [Abstract][Full Text] [Related]
5. Survival and impact of clinical prognostic factors in surgically treated metastatic renal cell carcinoma.
Tosco L; Van Poppel H; Frea B; Gregoraci G; Joniau S
Eur Urol; 2013 Apr; 63(4):646-52. PubMed ID: 23041360
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of long-term and short-term survivors of metastatic renal cell carcinoma treated with targeted therapies: results from the International mRCC Database Consortium.
Fay AP; Xie WL; Lee JL; Harshman LC; Bjarnason GA; Knox JJ; Ernst S; Wood L; Vaishamayan UN; Yuasa T; Tan MH; Rha SY; Donskov F; Agarwal N; Kollmannsberger CK; North SA; Rini BI; Choueiri TK; Heng DY
Clin Genitourin Cancer; 2015 Apr; 13(2):150-5. PubMed ID: 25458371
[TBL] [Abstract][Full Text] [Related]
7. Metastatic renal cell carcinoma to the pancreas: Clinical features and treatment outcome.
Shin TJ; Song C; Jeong CW; Kwak C; Seo S; Kang M; Chung J; Hong SH; Hwang EC; Park JY; Lee H
J Surg Oncol; 2021 Jan; 123(1):204-213. PubMed ID: 33047324
[TBL] [Abstract][Full Text] [Related]
8. Limitations of preoperative biopsy in patients with metastatic renal cell carcinoma: comparison to surgical pathology in 405 cases.
Abel EJ; Carrasco A; Culp SH; Matin SF; Tamboli P; Tannir NM; Wood CG
BJU Int; 2012 Dec; 110(11):1742-6. PubMed ID: 22503066
[TBL] [Abstract][Full Text] [Related]
9. Surgical treatment of atypical metastasis from renal cell carcinoma (RCC).
Antonelli A; Arrighi N; Corti S; Legramanti S; Zanotelli T; Cozzoli A; Cunico SC; Simeone C
BJU Int; 2012 Dec; 110(11 Pt B):E559-63. PubMed ID: 22639956
[TBL] [Abstract][Full Text] [Related]
10. Pattern of Care Study in Metastatic Renal-Cell Carcinoma in the Preimmunotherapy Era in Switzerland.
Sandmeier N; Rothschild SI; Rothermundt C; Cathomas R; Schardt J; Berthold D; von Burg P; Müller B; Beyer J; Vogt DR; Stenner F
Clin Genitourin Cancer; 2018 Aug; 16(4):e711-e718. PubMed ID: 29503245
[TBL] [Abstract][Full Text] [Related]
11. Management of favorable-risk patients with metastatic renal cell carcinoma: when to start and when to stop targeted therapy.
Powles T; Albers P
Clin Genitourin Cancer; 2012 Dec; 10(4):213-8. PubMed ID: 22939100
[TBL] [Abstract][Full Text] [Related]
12. Metastasectomy without systemic therapy in metastatic renal cell carcinoma: comparison with conservative treatment.
Kwak C; Park YH; Jeong CW; Lee SE; Ku JH
Urol Int; 2007; 79(2):145-51. PubMed ID: 17851285
[TBL] [Abstract][Full Text] [Related]
13. Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment.
Mancuso A; Di Paola ED; Leone A; Catalano A; Calabrò F; Cerbone L; Zivi A; Messina C; Alonso S; Vigna L; Caristo R; Sternberg CN
BJU Int; 2012 Jan; 109(2):200-6. PubMed ID: 22212284
[TBL] [Abstract][Full Text] [Related]
14. Time from nephrectomy as a prognostic factor in metastatic renal cell carcinoma patients receiving targeted therapies: overall results from a large cohort of patients.
Procopio G; Testa I; Verzoni E; Iacovelli R; Grassi P; Galli G; De Braud F; Saravia D; Salvioni R
Oncology; 2015; 88(3):133-8. PubMed ID: 25377648
[TBL] [Abstract][Full Text] [Related]
15. Economic burden of selected adverse events in patients aged ≥65 years with metastatic renal cell carcinoma.
Hagiwara M; Hackshaw MD; Oster G
J Med Econ; 2013 Nov; 16(11):1300-6. PubMed ID: 24004437
[TBL] [Abstract][Full Text] [Related]
16. Treatment of patients with metastatic renal cell cancer: a RAND Appropriateness Panel.
Halbert RJ; Figlin RA; Atkins MB; Bernal M; Hutson TE; Uzzo RG; Bukowski RM; Khan KD; Wood CG; Dubois RW
Cancer; 2006 Nov; 107(10):2375-83. PubMed ID: 17048248
[TBL] [Abstract][Full Text] [Related]
17. Current status of cytoreductive nephrectomy in metastatic renal cell carcinoma.
Harshman LC; Srinivas S
Expert Rev Anticancer Ther; 2007 Dec; 7(12):1749-61. PubMed ID: 18062749
[TBL] [Abstract][Full Text] [Related]
18. Prognostic role of pancreatic metastases from renal cell carcinoma: results from an Italian center.
Grassi P; Verzoni E; Mariani L; De Braud F; Coppa J; Mazzaferro V; Procopio G
Clin Genitourin Cancer; 2013 Dec; 11(4):484-8. PubMed ID: 23791435
[TBL] [Abstract][Full Text] [Related]
19. Characteristics and outcomes of tumors arising from the distal nephron.
Abern MR; Tsivian M; Polascik TJ; Coogan CL
Urology; 2012 Jul; 80(1):140-6. PubMed ID: 22626576
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of lymph node invasion in patients with metastatic renal cell carcinoma: a population-based perspective.
Lughezzani G; Capitanio U; Jeldres C; Isbarn H; Shariat SF; Arjane P; Widmer H; Perrotte P; Montorsi F; Karakiewicz PI
Cancer; 2009 Dec; 115(24):5680-7. PubMed ID: 19824083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
